The Effects of Daptomycin and Cytokines Production in Comparison With Vancomycin
Information source: Hospital Universitario Evangelico de Curitiba
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cellulitis
Intervention: Daptomycin (Drug); Vancomycin (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Hospital Universitario Evangelico de Curitiba
Summary
Primary: To determine the influence of daptomycin on inflammatory cytokine (IL-1, TNF and
IL-6) for the treatment of complicated cellulitis/erysipela compared with alternative
treatment (vancomycin or oxacillin). Secondary: To evaluate the clinical outcome of both
groups according to levels of the cytokines evaluated.
Clinical Details
Official title: Effects of Daptomycin in the Levels of IL-1, IL-6 and TNF in Patients With Complicated Cellulitis/Erisipela in Comparison With Vancomycin or Oxacillin
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Primary outcome: Cytokine levels
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Eligible patients will be age between 18 and 65 who required hospitalization and
parenteral antimicrobial therapy
2. Clinical documentation of cellulitis / erysipela
3. Documentation of a minimal surface area 75 cm2 based on the length and / or width of
the redness, swelling and / or induration
4. Documented fever, defined as oral or tympanic temperature greater than or equal to 38
° C
Exclusion Criteria:
1. Infections and other minor addition of erysipelas / cellulitis
2. Any recent use of antibacterial drug therapy (systemic or topical antibacterial drugs
within 14 days of enrollment)
3. Patients with clinical conditions that alter the interpretation of the primary
outcome as patients with neutropenia or compromised immune function, as HIV
infection, autoimmune disorders, use of corticosteroids.
4. Patients with known or suspected osteomyelitis.
5. Patients with suspected or confirmed septic arthritis.
6. Patients with complicated skin infections, such as diabetic foot infections. 7.
Chronic use of antipyretic drugs (eg, daily use of naproxen).
8. Less than 18 years of age. 9. pregnancy 10. Patients with mixed infections of
Gram-negative or be deleted since the therapy of gram-negative can influence the levels of
cytokines.
11. Patients with renal clearance <30 mL / min. 12. Patients who are not susceptible to
daptomycin or vancomycin. 13. Allergy to study medication.
Locations and Contacts
Hospital Universitário Evangelico de Curitiba, Curitiba, Parana 80730150, Brazil
Additional Information
Starting date: July 2012
Last updated: March 19, 2015
|